Annovis Bio (ANVS) Total Current Liabilities (2019 - 2026)

Annovis Bio has reported Total Current Liabilities for 8 years, with the latest figure at $12.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 410.73% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 410.73% YoY) and the FY2025 annual result came in at $3.6 million, down 6.33% from the prior year.
• Total Current Liabilities climbed to $12.8 million in Q1 2026 per ANVS's latest filing, from $3.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $12.8 million in Q1 2026 and troughed at $1.3 million in Q2 2022.
• A 5-year average of $4.2 million and a median of $3.7 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 411.02% in 2022, then slumped 48.58% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.7 million in 2022, then plunged by 44.42% to $4.3 million in 2023, then decreased by 9.3% to $3.9 million in 2024, then slipped by 6.33% to $3.6 million in 2025, then jumped by 251.84% to $12.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $12.8 million, $3.6 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.